title: Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.
abstract: The objective of the study was to compare the efficacy and tolerability of once-daily atomoxetine (< or =1.8 mg/(kg day) with those of placebo in children and adolescents (aged 6-16 years) with attention-deficit/hyperactivity disorder [ADHD (DSM-IV)]. This randomized, placebo-controlled, double-blind trial was conducted in Russia. The primary efficacy measure was baseline-to-end point changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) total score. Tolerability measures included treatment-emergent signs and symptoms (TESS), laboratory values and weight. Compared with patients in the placebo group (n = 33), patients treated with atomoxetine (n = 72) with a mean final dose of 1.4 mg/kg showed significantly greater improvement in ADHDRS-IV-Parent:Inv total score (least-squares mean: atomoxetine, -15.8; placebo, -11.4; p = 0.013). The most common TESS in the atomoxetine group included anorexia [atomoxetine, n = 13 (18.1%); placebo, n = 2 (6.1%)], somnolence, n = 11 versus n = 3 (15.3% vs. 9.1%, respectively), abdominal pain n = 9 versus n = 1 (12.5% vs. 3.0%, respectively) and nausea, n = 8 versus n = 1 (11.1% vs. 3.0%, respectively). Seven patients in the atomoxetine group and two in the placebo group experienced clinically important weight loss during the study (> or =7% from baseline; mean change, kg: atomoxetine, -0.6; placebo, 0.1; p = 0.032). Atomoxetine is efficacious in improving ADHD symptoms in children and adolescents. Atomoxetine treatment may be associated with a numerically higher incidence of anorexia, somnolence, abdominal pain and nausea, as well as statistically greater losses in body weight.
authors: Lilly Corporate Center, Lilly Research Laboratories, Indianapolis, IN 46285, USA. martenyi_ferenc@lilly.com
authors: Ferenc
authors: F
authors: Martenyi
authors: Nikolay N
authors: NN
authors: Zavadenko
authors: Natalia B
authors: NB
authors: Jarkova
authors: Alexandr A
authors: AA
authors: Yarosh
authors: Victoria O
authors: VO
authors: Soldatenkova
authors: Leonid M
authors: LM
authors: Bardenstein
authors: Irina A
authors: IA
authors: Kozlova
authors: Nikolay G
authors: NG
authors: Neznanov
authors: Olga I
authors: OI
authors: Maslova
authors: Andrey S
authors: AS
authors: Petrukhin
authors: Nina K
authors: NK
authors: Sukchotina
authors: Valeriy P
authors: VP
authors: Zykov
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000704:Analysis of Variance; D000855:Anorexia / Q000139:chemically induced; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010290:Parents; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D012426:Russia; D012890:Sleep / Q000187:drug effects; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride